Product Information
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.1904 per EA under NDC 33342005807. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Sep 27, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5; 300 mg/1; mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342005807
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA202414FDA Approved
9/27/2012
TE Code
AB
On Market Since
9/27/2012
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has been published 665 times since Nov 28, 2013, and over the history we have for it it has declined 62.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1904 per EA |
|---|---|
| All-time high | $0.5110 (Feb 12, 2014) |
| All-time low | $0.1656 (May 22, 2024) |
| 52-week high | $0.2129 |
| 52-week low | $0.1904 |
| Median price | $0.2959 |
| Average price | $0.3018 |
| Largest weekly change | +34.4% (Jun 19, 2024) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, manufactured by Macleods Pharmaceuticals Limited, is $0.1904 per EA (NDC 33342005807), effective Aug 19, 2026.
How has the price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has declined 62.5%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
Since Nov 28, 2013, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has ranged from a low of $0.1656 (May 22, 2024) to a high of $0.5110 (Feb 12, 2014), with a median of $0.2959 per EA.
Are there cheaper alternatives to IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, is $0.1698 per EA — about 11% below IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB.
Who manufactures IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB (NDC 33342005807) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.